Tushir et al., 2022
ViewPDFPublication | Publication Date | Title |
---|---|---|
US20240269125A1 (en) | Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent | |
RU2685730C1 (en) | Formulations of azaindole compounds | |
JP7492548B2 (en) | Compositions, devices, and methods for the treatment of alcohol use disorder | |
TWI680773B (en) | Pharmaceutical compositions having improved stability | |
JP6159084B2 (en) | Composition containing berberine or an analogue thereof for treating skin diseases associated with rosacea or blush | |
KR20130135296A (en) | Bepotastine compositions | |
EP3206665B1 (en) | Anhydrous liquid melatonin composition | |
MX2012013380A (en) | Liquid nasal spray containing low-dose naltrexone. | |
US20220280450A1 (en) | Prevention and treatment of coronavirus and related respiratory infections | |
JP2023517194A (en) | PLD for combination use in the treatment of coronavirus infections | |
CN104173286B (en) | Azelastine compositionss and purposes | |
US20050222258A1 (en) | Pharmaceuticals comprising shikonins as active constituent | |
US20140314857A1 (en) | Formulations for enhanced bioavailability of zanamivir | |
Tushir et al. | A descriptive review on pharmacokinetics and pharmacodynamics profile of an antifungal agent: clotrimazole | |
US20220016026A1 (en) | Naloxone formulations for sublingual and/or buccal administration | |
US7897640B2 (en) | Method of treatment of virus infections using shikonin compounds | |
US20210299077A1 (en) | Liposomal reduced glutathione (lrg) in combination with ivermectin for the treatment of covid-19 | |
EP4236931B1 (en) | Compositions comprising tetrahydrocannabinol for treating acute respiratory failure and/or acute respiratory distress syndrome | |
CN113490498A (en) | Aqueous suspension compositions, formulations and water dispersible dry compositions comprising 16 alpha-bromo-3 beta-hydroxy-5 alpha-androstan-17-one and hydrates, derivatives and analogs thereof | |
EP4259100A1 (en) | Materials and methods for treating viral and other medicinal conditions | |
Gandhi et al. | Medication conveyance through nose: Factors affecting and novel applications | |
WO2022228652A1 (en) | Means and method for treating viral infections | |
CN116056724A (en) | Methylthioninium compounds for the treatment of covd-19 | |
TW202203934A (en) | Receptor-interacting protein kinase inhibitors for treating conditions involving systemic hyperinflammatory response | |
CN111821300A (en) | Ritonavir liquid preparation and indications thereof |